Last mentioned: Mar 19, 2026
Insider Sale
CMO Rui Avelar sells 29,996 shares of EOLS stock.
Revenue Targets Raised
Management increases 2028 revenue goals citing market stabilization.
SEC Filing Update
Company files notice regarding changes or departures in director/officer roles.
Q4 Earnings Beat
Evolus reports record results and triggers a significant stock rally.
Evolus Chief Medical Officer Rui Avelar sold 29,996 shares of EOLS stock on March 19, 2026, following a period of significant price appreciation. The transaction occurs as the aesthetics company raises its long-term revenue targets and reports stabilizing trends in the neurotoxin market.
This page surfaces every story mentioning Evolysse across our finance coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running finance beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Evolysse was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |